VIDEO: Opus Genetics plans to bring therapies for rare retinal diseases to clinical trials

ByBen Yerxa, PhD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW ORLEANS — In this Healio Video Perspective from the Eyecelerator meeting, Ben Yerxa, PhD, acting CEO of Opus Genetics, discusses the company’s plans, including the beginning of trials of OPGx-001, designed to target the LCA5 gene.